It has been evaluated in patients with metastatic breast cancer, where it failed to meet endpoints, although some activity was observed in trastuzumab-refractory HER2-positive and in triple negative breast cancer (TNBC)13. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.